Skip to main content
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1975 Nov;48(5):423–429.

Progress of immunotherapy in the treatment of malignant melanoma.

S Ariyan
PMCID: PMC2595262  PMID: 1108459

Full text

PDF
423

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ariyan S., Gershon R. K. Augmentation of the adoptive transfer of specific tumor immunity by non-specifically immunized macrophages. J Natl Cancer Inst. 1973 Oct;51(4):1145–1148. doi: 10.1093/jnci/51.4.1145. [DOI] [PubMed] [Google Scholar]
  2. Bluming A. Z., Vogel C. L., Ziegler J. L., Mody N., Kamya G. Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann Intern Med. 1972 Mar;76(3):405–411. doi: 10.7326/0003-4819-76-3-405. [DOI] [PubMed] [Google Scholar]
  3. Klein E. Tumors of the skin. X. Immunotherapy of cutaneous and mucosal neoplasms. N Y State J Med. 1968 Apr 1;68(7):900–911. [PubMed] [Google Scholar]
  4. Krementz E. T., Samuels M. S., Wallace J. H., Benes E. N. Clinical experiences in immunotherapy of cancer. Surg Gynecol Obstet. 1971 Aug;133(2):209–217. [PubMed] [Google Scholar]
  5. Milton G. W., Brown M. M. The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. Aust N Z J Surg. 1966 May;35(4):286–290. doi: 10.1111/j.1445-2197.1966.tb03889.x. [DOI] [PubMed] [Google Scholar]
  6. Mitchen J. R., Moore G. E., Gerner R. E., Woods L. K. Interaction of human melanoma cell lines with autochthonous lymphoid cells. Yale J Biol Med. 1973 Dec;46(5):669–680. [PMC free article] [PubMed] [Google Scholar]
  7. Morton D. L., Eilber F. R., Holmes E. C., Hunt J. S., Ketcham A. S., Silverstein M. J., Sparks F. C. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974 Oct;180(4):635–643. doi: 10.1097/00000658-197410000-00029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Morton D. L., Malmgren R. A., Holmes E. C., Ketcham A. S. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968 Jul;64(1):233–240. [PubMed] [Google Scholar]
  9. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  10. Nomoto K., Gershon R. K., Waksman B. H. Role of nonimmunized macrophages in the rejection of an allotransplanted lymphoma. J Natl Cancer Inst. 1970 Mar;44(3):739–749. [PubMed] [Google Scholar]
  11. Simmons R. L., Rios A. Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG. Science. 1971 Nov 5;174(4009):591–593. doi: 10.1126/science.174.4009.591. [DOI] [PubMed] [Google Scholar]
  12. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES